Seres Therapeutics (MCRB) EBT (2016 - 2025)
Historic EBT for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to -$21.9 million.
- Seres Therapeutics' EBT rose 2335.02% to -$21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.2 million, marking a year-over-year increase of 1878.51%. This contributed to the annual value of -$117.3 million for FY2024, which is 3832.36% up from last year.
- Latest data reveals that Seres Therapeutics reported EBT of -$21.9 million as of Q3 2025, which was up 2335.02% from -$24.3 million recorded in Q2 2025.
- In the past 5 years, Seres Therapeutics' EBT ranged from a high of $68.3 million in Q3 2021 and a low of -$71.5 million during Q1 2023
- Over the past 5 years, Seres Therapeutics' median EBT value was -$33.4 million (recorded in 2024), while the average stood at -$28.4 million.
- In the last 5 years, Seres Therapeutics' EBT skyrocketed by 32286.69% in 2021 and then crashed by 149549.39% in 2023.
- Quarter analysis of 5 years shows Seres Therapeutics' EBT stood at -$49.7 million in 2021, then skyrocketed by 95.58% to -$2.2 million in 2022, then tumbled by 1495.49% to -$35.1 million in 2023, then rose by 18.99% to -$28.4 million in 2024, then increased by 23.03% to -$21.9 million in 2025.
- Its EBT stands at -$21.9 million for Q3 2025, versus -$24.3 million for Q2 2025 and -$26.6 million for Q1 2025.